Jump to main content
Jump to site search

Issue 49, 2015
Previous Article Next Article

Preclinical appraisal of terbutaline analogues in precipitation of autism spectrum disorder

Author affiliations

Abstract

Terbutaline is a β2 agonist used in the clinical management of asthma and as a tocolytic agent during pregnancy. In the recent past, the preterm use of terbutaline has been shown to hasten autistic-like symptoms in offsprings. For this reason, the present study was carried out to understand the effects of pharmacological analogues of terbutaline (salbutamol, salmeterol and montelukast) in the progression of ASDs in experimental animals. Pregnant rats were treated with salbutamol (10 mg kg−1, sc), salmeterol (10 μg kg−1, sc) and montelukast (10 mg kg−1, sc) and the offsprings were scrutinized for behavioral, biochemical, neuro-inflammatory and histopathological changes. The offsprings from the rats treated with salbutamol and montelukast were determined to be closely associated with various symptoms of ASDs.

Graphical abstract: Preclinical appraisal of terbutaline analogues in precipitation of autism spectrum disorder

Back to tab navigation

Publication details

The article was received on 10 Mar 2015, accepted on 13 Apr 2015 and first published on 13 Apr 2015


Article type: Communication
DOI: 10.1039/C5RA04213E
Author version
available:
Download author version (PDF)
RSC Adv., 2015,5, 39003-39011

  •   Request permissions

    Preclinical appraisal of terbutaline analogues in precipitation of autism spectrum disorder

    N. Sharma, S. Gautam, U. Devi, M. Singh, J. K. Rawat, N. Sethi, S. A. Saraf and G. Kaithwas, RSC Adv., 2015, 5, 39003
    DOI: 10.1039/C5RA04213E

Search articles by author

Spotlight

Advertisements